# Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

> **NCT04971161** · PHASE2 · COMPLETED · sponsor: **RHEACELL GmbH & Co. KG** · enrollment: 159 (actual)

## Conditions studied

- Skin Ulcer Venous Stasis Chronic

## Interventions

- **BIOLOGICAL:** allo-APZ2-CVU
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04971161
- **Lead sponsor:** RHEACELL GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-18
- **Primary completion:** 2025-11-25
- **Final completion:** 2025-11-25
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04971161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04971161, "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04971161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*